You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

~ Buy the GALLIUM GA 68 EDOTREOTIDE (gallium ga-68 edotreotide) Drug Profile, 2024 PDF Report in the Report Store ~

GALLIUM GA 68 EDOTREOTIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Gallium Ga 68 Edotreotide patents expire, and when can generic versions of Gallium Ga 68 Edotreotide launch?

Gallium Ga 68 Edotreotide is a drug marketed by Uihc Pet Imaging and is included in one NDA.

The generic ingredient in GALLIUM GA 68 EDOTREOTIDE is gallium ga-68 edotreotide. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium ga-68 edotreotide profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GALLIUM GA 68 EDOTREOTIDE?
  • What are the global sales for GALLIUM GA 68 EDOTREOTIDE?
  • What is Average Wholesale Price for GALLIUM GA 68 EDOTREOTIDE?
Summary for GALLIUM GA 68 EDOTREOTIDE
Drug patent expirations by year for GALLIUM GA 68 EDOTREOTIDE
Recent Clinical Trials for GALLIUM GA 68 EDOTREOTIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiangsu HengRui Medicine Co., Ltd.Phase 3
National Cancer Institute (NCI)Early Phase 1
M.D. Anderson Cancer CenterEarly Phase 1

See all GALLIUM GA 68 EDOTREOTIDE clinical trials

US Patents and Regulatory Information for GALLIUM GA 68 EDOTREOTIDE

GALLIUM GA 68 EDOTREOTIDE is protected by zero US patents and four FDA Regulatory Exclusivities.

FDA Regulatory Exclusivity protecting GALLIUM GA 68 EDOTREOTIDE

EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR THE LOCALIZATION OF KNOWN SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS
Exclusivity Expiration: ⤷  Sign Up

EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Uihc Pet Imaging GALLIUM GA 68 EDOTREOTIDE gallium ga-68 edotreotide SOLUTION;INTRAVENOUS 210828-001 Aug 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Uihc Pet Imaging GALLIUM GA 68 EDOTREOTIDE gallium ga-68 edotreotide SOLUTION;INTRAVENOUS 210828-001 Aug 21, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.